NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO – Get Free Report) traded up 0.4% on Friday . The stock traded as high as $2.46 and last traded at $2.31. 22,367 shares traded hands during trading, a decline of 94% from the average session volume of 397,830 shares. The stock had previously closed at $2.30.
NeuroBo Pharmaceuticals Trading Up 0.4 %
The firm has a fifty day simple moving average of $2.62 and a two-hundred day simple moving average of $3.49.
Institutional Investors Weigh In On NeuroBo Pharmaceuticals
Several institutional investors have recently added to or reduced their stakes in the business. Ferguson Wellman Capital Management Inc. bought a new stake in shares of NeuroBo Pharmaceuticals in the third quarter valued at approximately $50,000. Affinity Asset Advisors LLC bought a new position in NeuroBo Pharmaceuticals in the 2nd quarter worth approximately $432,000. Finally, Armistice Capital LLC purchased a new position in NeuroBo Pharmaceuticals in the 2nd quarter valued at approximately $3,373,000. 1.37% of the stock is owned by hedge funds and other institutional investors.
About NeuroBo Pharmaceuticals
NeuroBo Pharmaceuticals, Inc, a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is in Phase 2a clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), and has completed Phase 1 clinical trial for the treatment of type 2 diabetes mellitus (T2DM); and DA-1726, a novel oxyntomodulin analogue functioning as a GLP-1 receptor and glucagon receptor dual agonist, which is in preclinical development for the treatment of obesity.
Featured Articles
- Five stocks we like better than NeuroBo Pharmaceuticals
- Airline Stocks – Top Airline Stocks to Buy Now
- What’s Behind These 3 Recent Analyst Stock Upgrades?
- Quiet Period Expirations Explained
- Fast-Growing Companies That Are Still Undervalued
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Top Cybersecurity Stock Picks for 2025
Receive News & Ratings for NeuroBo Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroBo Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.